Traws Pharma, Inc. TRAW
Traws Pharma, Inc. ("Traws," "we," or the "Company") is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.
On April 1, 2024, the Company (then known as Onconova Therapeutics, Inc.) consummated a merger (the "Merger") with Trawsfynydd Therapeutics, Inc. ("Trawsfynydd"), a privately-held biotechnology company developing next-generation, best-in-class antivirals for influenza, COVID-19 and other infectious diseases. Prior to the Merger, the focus of our business was the discovery and development of novel products for patients with cancer. After completion of the Merger, the focus of our business expanded to include the development of novel therapies to target critical threats to human health in respiratory viral diseases. Following the Merger, we have four clinical programs: (i) tivoxavir marboxil, an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed to be administered as a single-dose for the treatment of bird flu and seasonal influenza; (ii) ratutrelvir, an inhibitor of the main protease (also known as 3CL protease) of the SAR-CoV-2 virus, the causative agent in COVID-19; (iii) narazaciclib (ON 123300), a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and (iv) rigosertib, administered alone or in combination for investigation in various cancers. Each of these programs is discussed in additional detail, below.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226.0K | $226.0K | $226.0K | $226.0K | $231.0K | $2.2M | $1.2M | $787.0K | $5.5M |
| R&D | — | — | $11.4M | $11.4M | $7.3M | $16.9M | $15.5M | $16.9M | $19.1M | $20.1M |
| SG&A | $8.5M | $12.3M | $9.1M | $8.4M | $9.4M | $8.3M | $8.3M | $7.6M | $7.4M | $9.2M |
| Total operating expenses | $20.7M | $142.6M | $20.5M | $19.9M | $16.7M | $25.2M | $23.9M | $24.5M | $26.5M | $29.2M |
| Operating income | -$17.9M | -$142.4M | -$20.3M | -$19.6M | -$16.5M | -$25.0M | -$21.7M | -$23.3M | -$25.7M | -$23.7M |
| Pre-tax income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M | -$25.2M | -$21.5M | -$20.5M | -$24.1M | -$19.7M |
| Income tax | — | — | — | — | — | $4.0K | $10.0K | $124.0K | $13.0K | $14.0K |
| Net income | $9.2M | -$166.5M | -$18.9M | -$19.0M | -$16.2M | -$25.2M | -$21.5M | -$20.6M | -$24.1M | -$19.7M |
| EPS, basic | 0.83 | -35.21 | -22.57 | -0.91 | -0.96 | -2.17 | — | — | — | — |
| EPS, diluted | 0.82 | -35.21 | -22.57 | -0.91 | -0.96 | -2.17 | -1.49 | -4.99 | -40.15 | -4.44 |
| Shares, diluted (wtd. avg.) | 8.4M | 1.6M | 839,554 | 20.9M | 16.8M | 11.6M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.8M | $21.3M | $20.8M | $38.8M | $55.1M | $19.0M | $22.7M | $17.0M | $4.0M | $21.4M |
| Receivables | $3.8M | $1.8M | $18.0K | $29.0K | $28.0K | $37.0K | $98.0K | $35.0K | $59.0K | $31.0K |
| Total current assets | $8.0M | $25.0M | $22.7M | $39.3M | $55.4M | $19.8M | $23.5M | $17.8M | $4.9M | $23.1M |
| Property, plant and equipment | $7.0K | $10.0K | $22.0K | $24.0K | $38.0K | $52.0K | $50.0K | $9.0K | $64.0K | $152.0K |
| Other intangibles | $2.5M | — | — | — | — | — | — | — | — | — |
| Total assets | $10.6M | $25.0M | $22.7M | $39.4M | $55.5M | $20.0M | $23.7M | $17.9M | $5.0M | $23.2M |
| Accounts payable | $5.7M | $8.2M | $5.6M | $3.9M | $2.8M | $4.8M | $4.3M | $4.0M | $6.2M | $5.3M |
| Total current liabilities | $11.1M | $11.5M | $9.2M | $8.0M | $6.1M | $10.0M | $8.3M | $8.4M | $10.0M | $10.2M |
| Total liabilities | $11.2M | $56.6M | $12.0M | $11.1M | $9.4M | $13.8M | $12.1M | $12.5M | $15.8M | $18.1M |
| Retained earnings | -$640.0M | -$649.2M | -$482.6M | -$463.7M | -$444.7M | -$428.6M | -$403.4M | -$381.9M | -$362.3M | -$338.2M |
| Total equity | -$629.0K | -$31.6M | $10.7M | $28.3M | $46.1M | $6.2M | $11.6M | $5.4M | -$10.9M | $5.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.2M | -$29.8M | -$17.9M | -$16.3M | -$19.5M | -$23.1M | -$20.8M | -$22.7M | -$23.8M | -$15.8M |
| Depreciation and amortisation | $61.0K | $12.0K | $16.0K | $14.0K | $14.0K | $13.0K | $14.0K | $55.0K | $88.0K | $96.0K |
| Stock-based compensation | $728.0K | $1.4M | $1.3M | $1.2M | $576.0K | $369.0K | $1.0M | $1.1M | $1.7M | $3.9M |
| Capital expenditure | $2.6M | $3.6M | $14.0K | — | — | $15.0K | $55.0K | — | — | — |
| Investing cash flow | -$2.6M | -$3.6M | -$14.0K | — | — | -$15.0K | -$55.0K | — | — | — |
| Financing cash flow | $3.2M | $34.0M | — | — | $55.6M | $19.4M | $26.6M | $35.7M | $6.4M | $17.4M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-067945.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $787.0K | $1.2M | $2.2M | $231.0K | $226.0K | $226.0K | $226.0K | $226.0K | $2.8M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$19.7M | -$24.1M | -$20.6M | -$21.5M | -$25.2M | -$16.2M | -$19.0M | -$18.9M | -$166.5M | $9.2M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |